<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457197</url>
  </required_header>
  <id_info>
    <org_study_id>112006-046</org_study_id>
    <nct_id>NCT00457197</nct_id>
  </id_info>
  <brief_title>Quetiapine for Bipolar Disorder and Alcohol Dependence</brief_title>
  <official_title>Quetiapine for Bipolar Disorder and Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether an investigational drug called quetiapine
      can treat bipolar disorder, improve mood and reduce alcohol use and craving.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim in the study is to determine if quetiapine treatment is associated with
      greater reduction in alcohol use than placebo in outpatients with bipolar disorder and
      alcohol dependence. We will also examine if quetiapine treatment is associated with greater
      reduction in alcohol craving than placebo in outpatients with bipolar disorder and alcohol
      dependence and if quetiapine treatment is associated with greater improvement in depressive
      symptoms than placebo in outpatients with bipolar disorder and alcohol dependence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Standard Drinks/Day Will Serve as the Primary Outcome Measure.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Heavy Drinking Days</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyltransferase (GGT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>GGT is a liver enzyme measurement (IU/I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>12 weeks</time_frame>
    <description>AST is a liver enzyme measurement (IU/I)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>ALT is a liver enzyme measurement (IU/I).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Depression (HRSD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The assessment is a clinician administered rating of depression with 17 questions. The total score is indicates level of depression within the following ranges: none (0-5), mild (6-10), moderate (11-15), severe (16-20), and very severe (21+).
Scale:
Minimum: 0 Maximum: 50 Lower score associated with better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inventory of Depressive Symptomatology-Self Report (IDS-SR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>IDS-SR is a self reported 30 item assessment to diagnose a major depressive episode.
Score:
Minimum: 0 Maximum: 84 Lower score associated with better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>This is an 11-item, observer rated measure of the severity of manic symptoms on a 5 point scale. The total score indicates overall severity of mania with a minimum of zero (indicating normalcy) and a maximum of 60 (indicating very severe).
Score:
Minimum: 0 Maximum: 60 Lower score associated with better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn Alcohol Craving Scale (PACS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PACS is a five-item self-administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking
Score:
Minimum: 0 Maximum: 30 Lower score associated with better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive ingredient matching the active medication in appearance.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar-pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
    <other_name>Xeroquel</other_name>
    <other_name>Ketipinor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients with a diagnosis of bipolar I or II disorder, depressed or mixed phase on
             the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental
             Disorders (SCID) and confirmed by interview with PI or co-I.

          -  Current diagnosis of alcohol dependence.

          -  Alcohol use (by self-report) of at least 15 drinks in the 7 days prior to baseline.

          -  Currently taking a mood stabilizer defined as lithium, divalproex/valproic acid,
             oxcarbazepine, or lamotrigine at a stable dose for &gt; 14 days.

          -  Men and women age 18-65 years old.

          -  English or Spanish speaking.

        Exclusion Criteria:

          -  Bipolar disorders other than bipolar I or II (e.g., not otherwise specified or
             cyclothymic disorders) based on the SCID and confirmed through clinical assessment by
             PI or co-I.

          -  Baseline Young Mania Rating Scale (YMRS) score &gt; 35 or Hamilton Depression Rating
             Scale (HRSD) 17 score &gt; 35.

          -  Current clinically significant psychotic features (hallucinations, delusions,
             disorganized thought processes).

          -  Evidence of clinically significant alcohol withdrawal symptoms defined as a Clinical
             Institute Withdrawal Assessment (CIWA-AR) score of &gt; 8.

          -  History of hepatic cirrhosis or baseline AST or ALT &gt; 3X upper limit of normal or
             other clinically significant findings on physical or laboratory examination.

          -  Mental retardation or other severe cognitive impairment.

          -  Prison or jail inmates.

          -  Pregnant or nursing women or women of childbearing age who will not use oral
             contraceptives, abstinence, or other acceptable methods of birth control during the
             study.

          -  Antipsychotic therapy within 14 days prior to randomization.

          -  Current carbamazepine or benzodiazepine therapy.

          -  Current treatment with medications shown to reduce alcohol consumption (naltrexone,
             acamprosate, disulfiram, or topiramate) in large randomized, controlled trials.

          -  Initiation of antidepressants or mood stabilizers or psychotherapy within past 2
             weeks.

          -  High risk for suicide, defined as any suicide attempts in the past 3 months or current
             suicidal ideation with plan and intent.

          -  Intensive outpatient treatment for substance abuse (AA, NA meetings, or other 12-step
             programs or weekly psychotherapy that started at least 14 days prior to randomization
             will be allowed).

          -  Current treatment with ketoconazole, itraconazole, erythromycin, or nefazodone.

          -  Severe or life-threatening medical condition (e.g., congestive heart failure, terminal
             cancer) or laboratory or physical examination findings consistent with serious medical
             illness (e.g., severe edema, atrial fibrillation, dangerously abnormal electrolytes).

          -  Diabetes mellitus by history or suspected from baseline blood sugar.

          -  History of cataracts or suspected cataracts on ophthalmic exam

          -  History of seizure disorder of any etiology; if a subject develops a seizure episode,
             s/he will be discontinued from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Sherwood Brown, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychoneuroendocrine Research Program</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <results_first_submitted>October 23, 2015</results_first_submitted>
  <results_first_submitted_qc>December 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 28, 2016</results_first_posted>
  <disposition_first_submitted>April 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 1, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 8, 2013</disposition_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bipolar disorder</keyword>
  <keyword>alcohol dependence</keyword>
  <keyword>mania</keyword>
  <keyword>manic disorder</keyword>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
        </group>
        <group group_id="P2">
          <title>Quetiapine</title>
          <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
        </group>
        <group group_id="B2">
          <title>Quetiapine</title>
          <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" spread="10.1"/>
                    <measurement group_id="B2" value="43.3" spread="8.2"/>
                    <measurement group_id="B3" value="41.5" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Married</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="2.4"/>
                    <measurement group_id="B2" value="13.6" spread="2.5"/>
                    <measurement group_id="B3" value="13.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mood states</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Depressed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed (both depression and mania at same time)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of treatment for drug/alcohol</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% Days Alcohol Use In Past Week</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.6" spread="26.1"/>
                    <measurement group_id="B2" value="74.2" spread="27.3"/>
                    <measurement group_id="B3" value="74.4" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% Days Heavy Alcohol Use In Past Week</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="30.1"/>
                    <measurement group_id="B2" value="53.0" spread="30.9"/>
                    <measurement group_id="B3" value="56.5" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Drinks per day</title>
          <units>drinks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="3.4"/>
                    <measurement group_id="B2" value="6.0" spread="3.4"/>
                    <measurement group_id="B3" value="6.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver enzymes</title>
          <units>IU/I</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>GGT (gamma-glutamyltransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="37.6"/>
                    <measurement group_id="B2" value="74.3" spread="69.3"/>
                    <measurement group_id="B3" value="61.05" spread="53.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST (aspartate aminotransferase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" spread="14.8"/>
                    <measurement group_id="B2" value="29.7" spread="13.5"/>
                    <measurement group_id="B3" value="28.6" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT (alanine aminotransferase)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="24.5"/>
                    <measurement group_id="B2" value="28.9" spread="17.3"/>
                    <measurement group_id="B3" value="29.0" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant medications</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lithium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Lithium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant medications</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Anticonvulsants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No anticonvulsants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant medications</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Antidepressants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No antidepressants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant medications</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sedatives/hypnotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No sedatives/hypnotics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mood and craving scales: Hamilton Rating Scale for Depression</title>
          <description>Minimum: 0 Maximum: 50 Lower score associated with better outcome Normal= 7 or less</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.3" spread="6.7"/>
                    <measurement group_id="B2" value="18.6" spread="7.0"/>
                    <measurement group_id="B3" value="18.5" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mood and craving scales: Inventory of Depressive Symptomatology-Self-Report</title>
          <description>Minimum= 0 Maximum= 84 Lower score associated with better outcome Normal= 7 or less</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="10.7"/>
                    <measurement group_id="B2" value="33.9" spread="14.6"/>
                    <measurement group_id="B3" value="31.3" spread="12.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mood and craving scales: Young Mania Rating Scale</title>
          <description>Minimum: 0 Maximum: 60 Lower score associated with better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="8.2"/>
                    <measurement group_id="B2" value="13.9" spread="6.7"/>
                    <measurement group_id="B3" value="13.8" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mood and craving scales: Penn Alcohol Craving Scale</title>
          <description>Minimum: 0 Maximum: 30 Lower score associated with better outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.2" spread="6.6"/>
                    <measurement group_id="B2" value="20.6" spread="6.3"/>
                    <measurement group_id="B3" value="19.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Standard Drinks/Day Will Serve as the Primary Outcome Measure.</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Standard Drinks/Day Will Serve as the Primary Outcome Measure.</title>
          <units>drinks</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" spread="2.465"/>
                    <measurement group_id="O2" value="8.09" spread="2.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline drinks/day used as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4709</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Heavy Drinking Days</title>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Heavy Drinking Days</title>
          <units>drinks</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="3.66"/>
                    <measurement group_id="O2" value="20.8" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline percent heavy drinking days included as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1272</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gamma-glutamyltransferase (GGT)</title>
        <description>GGT is a liver enzyme measurement (IU/I)</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 18 participants in placebo group and 11 participants in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Gamma-glutamyltransferase (GGT)</title>
          <description>GGT is a liver enzyme measurement (IU/I)</description>
          <population>Missing data for 18 participants in placebo group and 11 participants in the quetiapine group.</population>
          <units>IU/I</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.6" spread="8.34"/>
                    <measurement group_id="O2" value="66.0" spread="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline GGT used as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9642</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST)</title>
        <description>AST is a liver enzyme measurement (IU/I)</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 19 participants in placebo group and 11 participants in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST)</title>
          <description>AST is a liver enzyme measurement (IU/I)</description>
          <population>Missing data for 19 participants in placebo group and 11 participants in the quetiapine group.</population>
          <units>IU/I</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="2.92"/>
                    <measurement group_id="O2" value="31.1" spread="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline AST used as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7222</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT)</title>
        <description>ALT is a liver enzyme measurement (IU/I).</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 17 participants in placebo group and 13 participants in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <description>ALT is a liver enzyme measurement (IU/I).</description>
          <population>Missing data for 17 participants in placebo group and 13 participants in the quetiapine group.</population>
          <units>IU/I</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" spread="2.61"/>
                    <measurement group_id="O2" value="30.4" spread="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline ALT used as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1412</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Rating Scale for Depression (HRSD)</title>
        <description>The assessment is a clinician administered rating of depression with 17 questions. The total score is indicates level of depression within the following ranges: none (0-5), mild (6-10), moderate (11-15), severe (16-20), and very severe (21+).
Scale:
Minimum: 0 Maximum: 50 Lower score associated with better outcome</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 2 participants in placebo group and 3 participants in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression (HRSD)</title>
          <description>The assessment is a clinician administered rating of depression with 17 questions. The total score is indicates level of depression within the following ranges: none (0-5), mild (6-10), moderate (11-15), severe (16-20), and very severe (21+).
Scale:
Minimum: 0 Maximum: 50 Lower score associated with better outcome</description>
          <population>Missing data for 2 participants in placebo group and 3 participants in the quetiapine group.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="1.10"/>
                    <measurement group_id="O2" value="10.3" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline HRSD used as covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7071</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inventory of Depressive Symptomatology-Self Report (IDS-SR)</title>
        <description>IDS-SR is a self reported 30 item assessment to diagnose a major depressive episode.
Score:
Minimum: 0 Maximum: 84 Lower score associated with better outcome</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 4 participants in placebo group and 2 participants in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Inventory of Depressive Symptomatology-Self Report (IDS-SR)</title>
          <description>IDS-SR is a self reported 30 item assessment to diagnose a major depressive episode.
Score:
Minimum: 0 Maximum: 84 Lower score associated with better outcome</description>
          <population>Missing data for 4 participants in placebo group and 2 participants in the quetiapine group.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="1.79"/>
                    <measurement group_id="O2" value="21.9" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline IDS-SR used as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2569</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale (YMRS)</title>
        <description>This is an 11-item, observer rated measure of the severity of manic symptoms on a 5 point scale. The total score indicates overall severity of mania with a minimum of zero (indicating normalcy) and a maximum of 60 (indicating very severe).
Score:
Minimum: 0 Maximum: 60 Lower score associated with better outcome</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 6 participants in placebo group and 1 participant in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale (YMRS)</title>
          <description>This is an 11-item, observer rated measure of the severity of manic symptoms on a 5 point scale. The total score indicates overall severity of mania with a minimum of zero (indicating normalcy) and a maximum of 60 (indicating very severe).
Score:
Minimum: 0 Maximum: 60 Lower score associated with better outcome</description>
          <population>Missing data for 6 participants in placebo group and 1 participant in the quetiapine group.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.70" spread="1.09"/>
                    <measurement group_id="O2" value="8.48" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline YMRS used as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8814</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penn Alcohol Craving Scale (PACS)</title>
        <description>The PACS is a five-item self-administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking
Score:
Minimum: 0 Maximum: 30 Lower score associated with better outcome.</description>
        <time_frame>12 weeks</time_frame>
        <population>Missing data for 1 participants in placebo group and 5 participants in the quetiapine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
          </group>
          <group group_id="O2">
            <title>Quetiapine</title>
            <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
          </group>
        </group_list>
        <measure>
          <title>Penn Alcohol Craving Scale (PACS)</title>
          <description>The PACS is a five-item self-administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking
Score:
Minimum: 0 Maximum: 30 Lower score associated with better outcome.</description>
          <population>Missing data for 1 participants in placebo group and 5 participants in the quetiapine group.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="1.03"/>
                    <measurement group_id="O2" value="12.3" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline PACS used as a covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2473</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
Placebo: Inactive ingredient matching the active medication in appearance.</description>
        </group>
        <group group_id="E2">
          <title>Quetiapine</title>
          <description>This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
Quetiapine: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Victim of Sexual Assault</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Arrest for Public Intoxication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Larger sample size possibly needed for between-group differences in outcome measures. Pill counts not an optimum measure of medication adherence.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>E. Sherwood Brown, M.D., Ph.D., Professor</name_or_title>
      <organization>The University of Texas Southwestern Medical Center</organization>
      <phone>214-645-6950</phone>
      <email>sherwood.brown@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

